Publications by authors named "C Lasagni"
Article Synopsis
- Difficult-to-treat areas in psoriasis traditionally included the face, scalp, and genitals, but recent findings highlight the legs as a new challenging site, often affected even with biologic therapies.
- The study evaluated the effectiveness of the biologic drug risankizumab on leg psoriasis compared to other body areas in patients undergoing this treatment.
- Results showed that legs improved more slowly than other sites during initial weeks, but risankizumab is still considered effective for leg psoriasis despite this delayed response.
Background: Facial (FP) and genital psoriasis (GP) significantly affect patients' quality of life. Despite the advances in treatments, limited data on efficacy and safety are available on these difficult-to-treat areas. Guselkumab is an interleukin (IL)-23 inhibitor which has been proven effective in treating patients with moderate-to-severe plaque psoriasis.
View Article and Find Full Text PDF